US Bancorp’s Centessa Pharmaceuticals CNTA Stock Holding History

US Bancorp’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-19	Closed	–	–	4089
2021 Q2	$0	Buy	+19	New	+$447	﹤0.01%	4008

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

US Bancorp's CNTA Position: Q3 2021 in Review

US Bancorp sold out of Centessa Pharmaceuticals (CNTA) in Q3 2021, closing a stake of 19 shares.

US Bancorp first reported a position in CNTA in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 40 funds tracked by Wall St. Rank hold CNTA as of Q3 2021.

US Bancorp reported no remaining Centessa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
US Bancorp sold 19 Centessa Pharmaceuticals shares in Q3 2021.
US Bancorp first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 1 quarter.
US Bancorp's Centessa Pharmaceuticals position peaked at $0 in Q2 2021.
40 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2021.

Based on US Bancorp's 13F filing for Q3 2021, filed 10 Nov 2021.